Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCRcI in diffuse coronary artery disease
NCT04052191Phase 1Not yet recruiting
- Sponsor
- HONYA Medical
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MCRcI stem cells in coronary artery disease (CAD) (3 arms), sponsored by HONYA Medical. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 6 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
MCRcI stem cells
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04052191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052191.